{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:05:50Z","timestamp":1789380350296,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Xencor Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03130-x","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:38:13Z","timestamp":1789378693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed\/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-2611","authenticated-orcid":false,"given":"Guru Subramanian","family":"Guru Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-0048","authenticated-orcid":false,"given":"Jessica","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-8792","authenticated-orcid":false,"given":"Adam","family":"DuVall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Arana Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-0614","authenticated-orcid":false,"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"Baim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Runaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1798-9658","authenticated-orcid":false,"given":"Laura","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-4766","authenticated-orcid":false,"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-892X","authenticated-orcid":false,"given":"Tyce","family":"Kearl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-3564","authenticated-orcid":false,"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"3130_CR1","first-page":"3019","volume":"141","author":"SJ Si Lim","year":"2023","unstructured":"Si Lim SJ, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood. 2023;141:3019\u201330.","journal-title":"Blood"},{"key":"3130_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"3130_CR3","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1182\/blood-2007-07-101600","volume":"111","author":"P Munoz","year":"2008","unstructured":"Munoz P, Mittelbrunn M, de la Fuente H, Perez-Martinez M, Garcia-Perez A, Ariza-Veguillas A, et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood. 2008;111:3653\u201364.","journal-title":"Blood"},{"key":"3130_CR4","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","volume":"9","author":"F Morandi","year":"2018","unstructured":"Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Front Immunol. 2018;9:2722.","journal-title":"Front Immunol"},{"key":"3130_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1126\/science.8235624","volume":"262","author":"M Howard","year":"1993","unstructured":"Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 1993;262:1056\u20139.","journal-title":"Science"},{"key":"3130_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","volume":"160","author":"S Deaglio","year":"1998","unstructured":"Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol. 1998;160:395\u2013402.","journal-title":"J Immunol"},{"key":"3130_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood-2013-02-483511","volume":"122","author":"A Cagnetta","year":"2013","unstructured":"Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, et al. Intracellular NAD\u207a depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013;122:1243\u201355.","journal-title":"Blood"},{"key":"3130_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NW van de Donk","year":"2016","unstructured":"van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270:95\u2013112.","journal-title":"Immunol Rev"},{"key":"3130_CR9","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","volume":"104","author":"J Naik","year":"2019","unstructured":"Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 2019;104:e100\u2013e103.","journal-title":"Haematologica"},{"key":"3130_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"KL Bride","year":"2018","unstructured":"Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131:995\u20139.","journal-title":"Blood"},{"key":"3130_CR11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128:959\u201370.","journal-title":"Blood"},{"key":"3130_CR12","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","volume":"25","author":"E Drent","year":"2017","unstructured":"Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, et al. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Mol Ther. 2017;25:1946\u201358.","journal-title":"Mol Ther"},{"key":"3130_CR13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2023-174563","volume":"142","author":"B Pouleau","year":"2023","unstructured":"Pouleau B, Estoppey C, Suere P, Nallet E, Laurendon A, Monney T, et al. Preclinical characterization of ISB 1342, a CD38 x CD3 T-cell engager for relapsed\/refractory multiple myeloma. Blood. 2023;142:260\u201373.","journal-title":"Blood"},{"key":"3130_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3324\/haematol.2023.283814","volume":"109","author":"S Koslowski","year":"2024","unstructured":"Koslowski S, Glauben R, Habringer S, Burmeister T, Keller U, Bruggemann M, et al. Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia. Haematologica. 2024;109:661\u20135.","journal-title":"Haematologica"},{"key":"3130_CR15","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3324\/haematol.2020.268656","volume":"106","author":"M Kinder","year":"2021","unstructured":"Kinder M, Bahlis NJ, Malavasi F, De Goeij B, Babich A, Sendecki J, et al. Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma. Haematologica. 2021;106:2004\u20138.","journal-title":"Haematologica"},{"key":"3130_CR16","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/bloodadvances.2024013212","volume":"8","author":"E Martin-Sanchez","year":"2024","unstructured":"Martin-Sanchez E, Blanco L, Kim PS, Bisht K, Wang H, Van de Velde H, et al. Targeting CD38 with isatuximab and a novel CD38\/CD3xCD28 trispecific T-cell engager in older patients with acute myeloid leukemia. Blood Adv. 2024;8:3875\u20139.","journal-title":"Blood Adv"},{"key":"3130_CR17","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1182\/blood.V126.23.1798.1798","volume":"126","author":"GL Moore","year":"2015","unstructured":"Moore GL, Lee SH, Schubbert S, Miranda Y, Rashid R, Pong EW, et al. Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 \u00d7 Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma. Blood. 2015;126:1798\u20131798.","journal-title":"Blood"},{"key":"3130_CR18","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","volume":"25","author":"CL Zuch de Zafra","year":"2019","unstructured":"Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL, et al. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38\/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. Clin Cancer Res. 2019;25:3921\u201333.","journal-title":"Clin Cancer Res"},{"key":"3130_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-017-0293-7","volume":"5","author":"Q Xue","year":"2017","unstructured":"Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, McConnell T, et al. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. J Immunother Cancer. 2017;5:85.","journal-title":"J Immunother Cancer"},{"key":"3130_CR20","doi-asserted-by":"publisher","first-page":"12690","DOI":"10.1182\/blood-2022-169198","volume":"140","author":"F Furqan","year":"2022","unstructured":"Furqan F, Xu H, Zurko J, Fenske TS, Johnson B, Hamadani M, et al. Single Cell Cytokine Analyses of Bispecific, Tandem, Anti-CD20, Anti-CD19 CAR T-Cells from Patients with Relapsed, Refractory B-Cell Malignancies. Blood. 2022;140:12690\u20131.","journal-title":"Blood"},{"key":"3130_CR21","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","volume":"109","author":"DJ DeAngelo","year":"2007","unstructured":"DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136\u201342.","journal-title":"Blood"},{"key":"3130_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1200\/OP.22.00237","volume":"18","author":"GS Guru Murthy","year":"2022","unstructured":"Guru Murthy GS, Atallah E. Relapsed\/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges. JCO Oncol Pract. 2022;18:489\u201390.","journal-title":"JCO Oncol Pract"},{"key":"3130_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024;391:320\u201333.","journal-title":"N Engl J Med"},{"key":"3130_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.2","volume":"7","author":"SS Hoseini","year":"2017","unstructured":"Hoseini SS, Cheung NK. Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J. 2017;7:e522.","journal-title":"Blood Cancer J"},{"key":"3130_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","volume":"13","author":"DG Guy","year":"2018","unstructured":"Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Hematol Malig Rep. 2018;13:417\u201325.","journal-title":"Curr Hematol Malig Rep"},{"key":"3130_CR26","doi-asserted-by":"crossref","unstructured":"Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, et al. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. J Immunother Cancer. 2022;10:e003882.","DOI":"10.1136\/jitc-2021-003882"},{"key":"3130_CR27","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","volume":"7","author":"F Ravandi","year":"2023","unstructured":"Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, et al. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia. Blood Adv. 2023;7:6492\u2013505.","journal-title":"Blood Adv"},{"key":"3130_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1007783","volume":"12","author":"X Zhong","year":"2022","unstructured":"Zhong X, Ma H. Targeting CD38 for acute leukemia. Front Oncol. 2022;12:1007783.","journal-title":"Front Oncol"},{"key":"3130_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13742","volume":"17","author":"R Narayan","year":"2024","unstructured":"Narayan R, Pierola AA, Donnellan WB, Yordi AM, Abdul-Hay M, Platzbecker U, et al. First-in-human study of JNJ-67571244, a CD33 x CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome. Clin Transl Sci. 2024;17:e13742.","journal-title":"Clin Transl Sci"},{"key":"3130_CR30","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1182\/blood.V128.22.5268.5268","volume":"128","author":"M Eveillard","year":"2016","unstructured":"Eveillard M, Floc\u2019h V, Robillard N, Debord C, Wuilleme S, Garand R, et al. CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy. Blood. 2016;128:5268\u20135268.","journal-title":"Blood"},{"key":"3130_CR31","doi-asserted-by":"crossref","unstructured":"Tembhare PR., Sriram H, Khanka T, Chatterjee G, Panda D, Ghogale S, et al. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. J Immunother Cancer. 2020;8:e000630.","DOI":"10.1136\/jitc-2020-000630"},{"key":"3130_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01300-8","volume":"11","author":"M Farber","year":"2021","unstructured":"Farber M, Chen Y, Arnold L, Mollmann M, Boog-Whiteside E, Lin YA, et al. Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. Sci Rep. 2021;11:22062.","journal-title":"Sci Rep"},{"key":"3130_CR33","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puyo P, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144:2237\u201347.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03130-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:38:17Z","timestamp":1789378697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03130-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":33,"alternative-id":["3130"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03130-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Guru Subramanian Guru Murthy reports the following outside the submitted work - Cardinal Health (Honoraria), BMS (Advisory board), BeiGene (Advisory board), Pfizer (Advisory board), Gilead\/Kite (Advisory board), Astra Zeneca Gilead\/Kite (Advisory board), Syndax Gilead\/Kite (Advisory board), Amgen (Speaker Bureau), Rigel (Speaker Bureau), Daiichi Sankyo Gilead\/Kite (Advisory board), all outside the submitted work. Dr Bijal Shah reports the following outside the submitted work \u2013 Bristol Myers Squibb: Consultancy; AstraZeneca: Consultancy; Jazz Pharmaceuticals, Kite-Gilead, Servier: Research Funding; Pepromene Bio: DSMB; Amgen: Consultancy; Adaptive Biotechnologies: Consultancy; Eli Lilly: Consultancy; Kite Pharma: Consultancy; Jazz Pharmaceuticals: Consultancy; Autolus, Beigene, Century Therapeutics, Deciphera, Jazz, Kite\/Gilead, Pfizer, Precision Biosciences, Novartis, Takeda: Consultancy. Dr Talha Badar reports the following outside the submitted work \u2013 advisory boards for Amgen, Takeda, Syndax, and MorphoSys; Research funding from Takeda and Amgen. Dr Arana Yi reports the following outside the submitted work - Consultancy\/Advisory Board: Blueprint Sanofi, Cogent Pharmaceuticals, Brystol Myers Squibb, Dava Oncology, Curio Science, Medscape and Research Funding from Blueprint Pharmaceuticals. Dr Jessica Leonard reports the following outside the submitted work - Kite (Consultancy), Autolus (Consultancy), Amgen (Consultancy), AstraZeneca (Consultancy), Pfizer (Consultancy), Adaptive Biotechnologies (Consultancy), Takeda (Consultancy), Abbvie, (Research Funding). Dr Laura Michaelis reports the following outside the submitted work - Incyte (Consultancy), Merck (Consultancy). Dr Sameem Abedin reports the following outside the submitted work - consultancy for Sanofi, Incyte Inc, Servier, and Soba; and received research funding from Actinium, AltruBio, and Incyte. Dr. Ehab Atallah reports the following outside the submitted work \u2013 Abbvie (consultant), Novartis (Consultant, research support), Amgen (Research Funding), BMS (Consultant), Takeda (Consultant), Syndax (Consultant), Actinium (Consultant), Handa (Consultant), Uptodate (Patents and Royalties) all outside the submitted work. All other authors report no relevant conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}